Management of Gastrointestinal Bleeding in Patients on Apixaban
Initial Assessment and Classification
- The American College of Cardiology recommends stratifying patients as hemodynamically stable or unstable to determine management urgency 3, 4
- For stable patients, the American College of Cardiology categorizes the bleed as major or non-major, with major bleeding defined as bleeding at a critical site, hemodynamic instability, or clinically overt bleeding with hemoglobin decrease ≥2 g/dL or requiring ≥2 units of RBC transfusion 1
Immediate Management
- The American College of Cardiology recommends stopping apixaban immediately and providing supportive care and volume resuscitation for patients with major GI bleeding 1, 2, 3
- The American College of Cardiology suggests considering administering andexanet alfa, a specific reversal agent for apixaban, for severe or life-threatening bleeding 2
- Discontinue any concomitant antiplatelet agents for patients with GI bleeding on apixaban 1, 3
Transfusion Management
- The American College of Cardiology and Gut recommend using restrictive RBC transfusion thresholds (Hb trigger 70 g/L and target 70-90 g/L) for patients with GI bleeding on apixaban 3, 4
- For patients with cardiovascular disease, a higher threshold (Hb trigger 80 g/L and target 100 g/L) is recommended 3, 5
Diagnostic Workup
- CT angiography is recommended to localize the bleeding site for hemodynamically unstable patients or those with active bleeding 3, 4
- If no source is identified on CT angiography and the patient is unstable, perform immediate upper endoscopy 3, 4
Considerations for Restarting Anticoagulation
- The American College of Cardiology recommends determining if there's a clinical indication for continued anticoagulation after bleeding has been controlled, considering factors such as critical site bleeding, high risk of rebleeding, and thrombotic risk 1
- For patients with high thrombotic risk, consider resuming anticoagulation within 7 days after bleeding has stopped 3, 4